Impact of the COVID-19 pandemic on the quality of life of early breast cancer patients undergoing adjuvant chemotherapy – an observational, multicenter study
DOI:
https://doi.org/10.2340/1651-226X.2025.43691Keywords:
breast cancer, covid-19 pandemic, health-related quality of life, HRQoL, EORTC QLQ-C30, adjuvant chemotherapyAbstract
Background and purpose: We evaluated the impact of the coronavirus disease 2019 (COVID-19) pandemic on health-related quality of life (HRQoL) in early-stage breast cancer patients receiving adjuvant chemotherapy.
Patients and methods: The study involved 180 patients with stage I–III breast cancer who initiated adjuvant chemotherapy between June 2020 and May 2021. The pre-pandemic comparison data included 113 early breast cancer patients who began adjuvant chemotherapy between November 2018 and August 2019. HRQoL was assessed using the EORTC QLQ-C30 at baseline and again after 3 and 6 months. The subscales were compared between the COVID-19 pandemic and the pre-pandemic eras.
Results: We observed deterioration on almost all HRQoL subscales of the patients treated during the pandemic from baseline to 3 months. After the chemotherapy at 6 months, the scales remained deteriorated, whereas only appetite loss and emotional functioning improved. A comparison between the pandemic and the pre-pandemic eras revealed that several HRQoL subscales showed better results during chemotherapy in the pandemic era. Global health and role functioning at 6 months presented declined levels during the pandemic.
Interpretation: The well-being of breast cancer patients during the chemotherapy treatment in the pandemic era was moderately better than in the pre-pandemic era. Patients in the pandemic era might have reported fewer symptoms during the treatment, as the focus was on the COVID-19 pandemic and its restrictions.
Downloads
References
Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–91.
https://doi.org/10.1158/2159-8290.CD-20-0422 DOI: https://doi.org/10.1158/2159-8290.CD-20-0422
Ng JS, Hamilton DG. Assessing the impact of the COVID-19 pandemic on breast cancer screening and diagnosis rates: a rapid review and meta-analysis. J Med Screen. 2022;29:209–18.
https://doi.org/10.1177/09691413221101807 DOI: https://doi.org/10.1177/09691413221101807
COVIDSurg Collaborative. Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study. Lancet Oncol. 2021;22:1507–17. DOI: https://doi.org/10.1016/S1470-2045(21)00493-9
Zhao F, Henderson TO, Cipriano TM, Copley BL, Liu M, Burra R, et al. The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort. Cancer. 2021;127:4072–80.
https://doi.org/10.1002/cncr.33798 DOI: https://doi.org/10.1002/cncr.33798
Swainston J, Chapman B, Grunfeld EA, Derakshan N. COVID-19 lockdown and its adverse impact on psychological health in breast cancer. Front Psychol. 2020;11:2033.
https://doi.org/10.3389/fpsyg.2020.02033 DOI: https://doi.org/10.3389/fpsyg.2020.02033
Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134–50.
https://doi.org/10.1016/S0140-6736(16)31891-8 DOI: https://doi.org/10.1016/S0140-6736(16)31891-8
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.
https://doi.org/10.1016/S0140-6736(05)66544-0 DOI: https://doi.org/10.1016/S0140-6736(05)66544-0
Al-Batran SE, Hozaeel W, Tauchert FK, Hofheinz RD, Hinke A, Windemuth-Kieselbach C, et al. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol. 2015;26:1244–8.
https://doi.org/10.1093/annonc/mdv129 DOI: https://doi.org/10.1093/annonc/mdv129
Binotto M, Reinert T, Werutsky G, Zaffaroni F, Schwartsmann G. Health-related quality of life before and during chemotherapy in patients with early-stage breast cancer. Ecancermedicalscience. 2020;14:1007.
https://doi.org/10.3332/ecancer.2020.1007 DOI: https://doi.org/10.3332/ecancer.2020.1007
Zhou K, Bellanger M, Le Lann S, Robert M, Frenel JS, Campone M. The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life. Front Oncol. 2022;12:925534.
https://doi.org/10.3389/fonc.2022.925534 DOI: https://doi.org/10.3389/fonc.2022.925534
Browall M, Ahlberg K, Karlsson P, Danielson E, Persson LO, Gaston-Johansson F. Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women. Eur J Oncol Nurs. 2008;12:180–9.
https://doi.org/10.1016/j.ejon.2008.01.005 DOI: https://doi.org/10.1016/j.ejon.2008.01.005
Di Nardo P, Lisanti C, Garutti M, Buriolla S, Alberti M, Mazzeo R, et al. Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects. Expert Opin Drug Saf. 2022;21:1341–55.
https://doi.org/10.1080/14740338.2022.2151584 DOI: https://doi.org/10.1080/14740338.2022.2151584
Grasic Kuhar C, Gortnar Cepeda T, Kurzeder C, Vetter M. Changes in the quality of life of early breast cancer patients and comparison with the normative Slovenian population. Radiol Oncol. 2023;57:211–9.
https://doi.org/10.2478/raon-2023-0019 DOI: https://doi.org/10.2478/raon-2023-0019
Bottomley A, Therasse P, Piccart M, Efficace F, Coens C, Gotay C, et al. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol. 2005;6:287–94.
https://doi.org/10.1016/S1470-2045(05)70100-5 DOI: https://doi.org/10.1016/S1470-2045(05)70100-5
Ibrahim EY, Domenicano I, Nyhan K, Elfil M, Mougalian SS, Cartmel B, et al. Cognitive effects and depression associated with taxane-based chemotherapy in breast cancer survivors: a meta-analysis. Front Oncol. 2021;11:642382.
https://doi.org/10.3389/fonc.2021.642382 DOI: https://doi.org/10.3389/fonc.2021.642382
Culbertson MG, Bennett K, Kelly CM, Sharp L, Cahir C. The psychosocial determinants of quality of life in breast cancer survivors: a scoping review. BMC Cancer. 2020;20:948.
https://doi.org/10.1186/s12885-020-07389-w DOI: https://doi.org/10.1186/s12885-020-07389-w
Karademas EC, Mylona E, Mazzocco K, Pat-Horenczyk R, Sousa B, Oliveira-Maia AJ, et al. Well-being trajectories in breast cancer and their predictors: a machine-learning approach. Psychooncology. 2023;32:1762–70.
https://doi.org/10.1002/pon.6230 DOI: https://doi.org/10.1002/pon.6230
Jones EAK, Mitra AK, Bhuiyan AR. Impact of COVID-19 on mental health in adolescents: a systematic review. Int J Environ Res Public Health. 2021;18:2470.
https://doi.org/10.3390/ijerph18052470 DOI: https://doi.org/10.3390/ijerph18052470
Pini S, Buck C, Lally P, Beeken R, Fisher A. The impact of the COVID-19 pandemic on mental health and quality of life in people living with and beyond breast, prostate and colorectal cancer – a qualitative study. BMC Psychol. 2024;12:25.
https://doi.org/10.1186/s40359-023-01471-1 DOI: https://doi.org/10.1186/s40359-023-01471-1
Svendsen K, Leithe S, Trewin-Nybråten CB, Balto A, Nes LS, Meland A et al. How did breast cancer patients fare during different phases of the COVID-19 pandemic in Norway compared to age-matched controls? Cancers (Basel). 2024;16:602.
https://doi.org/10.3390/cancers16030602 DOI: https://doi.org/10.3390/cancers16030602
Pettini G, Sanchini V, Pat-Horenczyk R, Sousa B, Masiero M, Marzorati C, et al. Predicting effective adaptation to breast cancer to help women BOUNCE back: protocol for a multicenter clinical pilot study. JMIR Res Protoc. 2022;11:e34564.
https://doi.org/10.2196/34564 DOI: https://doi.org/10.2196/34564
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.
https://doi.org/10.1093/jnci/85.5.365 DOI: https://doi.org/10.1093/jnci/85.5.365
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 scoring manual. 3rd ed. Brüssel: European Organisation of Research and Treatment of Cancer; 2001.
Whittaker AL, George RP, O’Malley L. Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: a systematic review and meta-analysis. Sci Rep. 2022;12:2135.
https://doi.org/10.1038/s41598-022-05682-1 DOI: https://doi.org/10.1038/s41598-022-05682-1
Berger NF, Zimmerman BS, Seidman D, Cascetta KP, Moshier E, Nezolosky M, et al. Impact of the COVID-19 pandemic on cancer care and quality of life for patients with breast and gynecologic malignancies: a single-center survey-based study. J Patient Exp. 2022;9:23743735221077543.
https://doi.org/10.1177/23743735221077543 DOI: https://doi.org/10.1177/23743735221077543
Chen G, Wu Q, Jiang H, Zhang H, Peng J, Hu J, et al. Fear of disease progression and psychological stress in cancer patients under the outbreak of COVID-19. Psychooncology. 2020;29:1395–8.
https://doi.org/10.1002/pon.5451 DOI: https://doi.org/10.1002/pon.5451
Bargon CA, Batenburg MCT, van Stam LE, Mink van der Molen DR, van Dam IE, van der Leij F, et al. Impact of the COVID-19 pandemic on patient-reported outcomes of breast cancer patients and survivors. JNCI Cancer Spectr. 2020;5:pkaa104.
https://doi.org/10.1093/jncics/pkaa104 DOI: https://doi.org/10.1093/jncics/pkaa104
Bartmann C, Fischer LM, Hübner T, Müller-Reiter M, Wöckel A, McNeill RV, et al. The effects of the COVID-19 pandemic on psychological stress in breast cancer patients. BMC Cancer. 2021;21:1356.
https://doi.org/10.1186/s12885-021-09012-y DOI: https://doi.org/10.1186/s12885-021-09012-y
İlgün AS, Özmen V. The impact of the COVID-19 pandemic on breast cancer patients. Eur J Breast Health. 2021;18:85–90.
https://doi.org/10.4274/ejbh.galenos.2021.2021-11-5 DOI: https://doi.org/10.4274/ejbh.galenos.2021.2021-11-5
Vanni G, Pellicciaro M, Materazzo M, Pedini D, Portarena I, Buonomo C, et al. Advanced stages and increased need for adjuvant treatments in breast cancer patients: the effect of the one-year COVID-19 pandemic. Anticancer Res. 2021;41:2689–96.
https://doi.org/10.21873/anticanres.15050 DOI: https://doi.org/10.21873/anticanres.15050
Koca B, Yildirim M. Delay in breast cancer diagnosis and its clinical consequences during the coronavirus disease pandemic. J Surg Oncol. 2021;124:261–7.
https://doi.org/10.1002/jso.26581 DOI: https://doi.org/10.1002/jso.26581
Johansson ALV, Larønningen S, Skovlund CW, Kristiansen MF, Mørch LS, Friis S, et al. The impact of the COVID-19 pandemic on cancer diagnosis based on pathology notifications: a comparison across the Nordic countries during 2020. Int J Cancer. 2022;151:381–95.
https://doi.org/10.1002/ijc.34029 DOI: https://doi.org/10.1002/ijc.34029
Musoro JZ, Coens C, Sprangers MAG, Brandberg Y, Groenvold M, Flechtner HH, et al. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types. Eur J Cancer. 2023;188:171–82.
https://doi.org/10.1016/j.ejca.2023.04.027 DOI: https://doi.org/10.1016/j.ejca.2023.04.027
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Marie Tuomarila, Paula Poikonen-Saksela, Haridimos Kondylakis, Johanna Mattson, Päivi Auvinen, Arja Jukkola, Ilja Kalashnikov, Jussi Koivunen, Okko-Sakari Kääriäinen, Kaisa Sunela, Meri Utriainen, Pia Vihinen, Sirpa Leppä, Peeter Karihtala
This work is licensed under a Creative Commons Attribution 4.0 International License.
